Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

• Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction.

• Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo.

• Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, including machine learning and data science tools for exploring genetic design space.

• The agreement represents Ginkgo's largest acquisition to date and is expected to significantly enhance Ginkgo's platform by integrating robust automation and software capabilities.

• Ginkgo customers will also benefit from expanding Ginkgo's library of biological assets ("Codebase") following the transaction.

• The transaction is expected to be completed by the first quarter of 2023.

• Price Action: DNA shares are down 4.62% at $2.79, and ZY stock is up 18.8% at $2.38 during the market session on the last check Monday.

See more from Benzinga

• Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product

• Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.